Updates

Benchmark

August 2016

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

Benchmark’s H1 saw sales up 142% to £48m with an operating loss of £15.2m. Massive investment of course continues across the group and management suggests this and acquisition costs are stripped out. On this basis, EBITDA from products on the market or “trading ebitda” went up from £1.2m to £9.5m, the bulk of which related to INVE.There are now five arms, three substantial ones.The Animal Health division (trading ebitda £2m vs £0.5m) saw its market share recover from last year’s competitive onslaught for Byelice/Salmosan after new supply agreements were signed with longstanding customers (lower price, fixed volume contracts). A new sea bass vaccine was launched and t ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Victoria

On The Beach

Benchmark - Woodford overhang clears (July 2019)

Benchmark (July 2018)

Benchmark - Product launches set for big uptick (December 2017)

Benchmark (November 2017)

Benchmark - Outer year forecasts will rise once capacity comes on stream (September 2016)

Benchmark - Down but certainly not out (March 2016)

Benchmark (January 2016)

Benchmark - Reverse takeover talks (November 2015)

Benchmark - Buys tilapia breeding business for £11m (September 2015)

Benchmark (July 2015)

Benchmark (May 2015)

Benchmark - Acquires veterinary training business (March 2015)

Benchmark (February 2015)

Benchmark (December 2014)

Benchmarck - Exciting new vaccine for cats (September 2014)

Benchmark - Not long for the new products to emerge (July 2014)

Benchmark - Top dog in aquafarming sector (May 2014)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X